Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

(eukaryotic translation initiation factor) eIF2 Inhibitors

Eukaryotic initiation factors (eIFs) are a crucial group of proteins involved in the initiation phase of protein translation in eukaryotic cells. This process, known as translation initiation, marks the beginning of protein synthesis, and it plays a central role in regulating gene expression. eIFs orchestrate the assembly of ribosomes on messenger RNA (mRNA) and the recruitment of transfer RNA (tRNA) molecules bearing amino acids, enabling the synthesis of polypeptide chains. This intricate process is highly regulated and essential for proper cellular function. One of the key events in translation initiation is the formation of the eIF complex known as the eIF4F complex, which consists of eIF4E, eIF4A, and eIF4G. eIF4E binds to the mRNA cap structure, eIF4A serves as an RNA helicase, and eIF4G acts as a scaffold protein facilitating the interaction between various translation factors. This complex plays a pivotal role in mRNA recruitment to ribosomes, allowing efficient translation to occur. Additionally, eIF2 is another critical factor in translation initiation, responsible for delivering the initiator tRNA to the ribosome's P-site.

eIF inhibitors are a class of chemical compounds that target key components of the eIF signaling pathway, disrupting their normal functions and consequently impeding the initiation of protein translation. These inhibitors may act at various stages of translation initiation, including the inhibition of eIF4F complex formation, disruption of eIF2 function, or interference with RNA helicase activity. By interfering with these critical steps, eIF inhibitors can modulate the rate of protein synthesis, potentially leading to global changes in gene expression.

SEE ALSO...

Items 1 to 10 of 16 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Eeyarestatin I

412960-54-4sc-358130B
sc-358130
sc-358130A
sc-358130C
sc-358130D
sc-358130E
5 mg
10 mg
25 mg
50 mg
100 mg
500 mg
$114.00
$203.00
$354.00
$697.00
$1363.00
$5836.00
12
(1)

Eeyarestatin I inhibits eIF2α dephosphorylation, leading to sustained phosphorylation and decreased protein synthesis.

GSK 2606414

1337531-36-8sc-490182
sc-490182A
5 mg
25 mg
$163.00
$572.00
(0)

GSK2606414 inhibits the activity of PERK, a kinase that phosphorylates eIF2α, reducing eIF2α phosphorylation levels.

Sephin1

13098-73-2sc-507502
5 mg
$578.00
(0)

Sephin1 selectively inhibits the eIF2α phosphatase, GADD34, preventing eIF2α dephosphorylation and reducing translation.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$138.00
$380.00
101
(4)

Cisplatin indirectly affects eIF2α by causing DNA damage, triggering the integrated stress response and eIF2α phosphorylation.

Etoposide (VP-16)

33419-42-0sc-3512B
sc-3512
sc-3512A
10 mg
100 mg
500 mg
$51.00
$231.00
$523.00
63
(1)

Etoposide causes DNA damage, which could lead to a cellular stress response, potentially diverting cellular resources from RNAi pathways and thus down-regulating eIF2C2.

Fluorouracil

51-21-8sc-29060
sc-29060A
1 g
5 g
$37.00
$152.00
11
(1)

By acting as a pyrimidine analog, 5-Fluorouracil might disrupt nucleotide metabolism. This disruption could indirectly affect RNAi components by hampering RNA synthesis, leading to decreased eIF2C2 levels.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$74.00
$243.00
$731.00
$2572.00
$21848.00
53
(3)

Actinomycin D hinders RNA synthesis by intercalating DNA. This can lead to a general down-regulation of RNA-derived processes, which might include a decrease in eIF2C2 levels.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$41.00
$84.00
$275.00
127
(6)

By inhibiting protein synthesis, Cycloheximide might halt the production of new eIF2C2 molecules, leading to a net decrease in eIF2C2 as existing proteins degrade.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$176.00
$426.00
43
(3)

DNA damage from Doxorubicin may cause the cell to prioritize DNA repair over regular functions, potentially suppressing RNAi machinery and decreasing eIF2C2 levels.

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$58.00
$186.00
$94.00
21
(2)

Camptothecin's inhibition of topoisomerase I can cause DNA damage, which might lead to a reduced focus on RNAi processes and subsequent lower eIF2C2 expression.